Sole Source NITRIC OXIDE 800 PPM GAS BPA
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Defense Health Agency (DHA) has issued a Special Notice (Notice of Intent) to award a sole source, firm-fixed-price 5-Year Blanket Purchase Agreement (BPA) to INO THERAPEUTICS, LLC for Nitric Oxide 800 PPM Gas. This notice is not a request for competitive proposals, but an opportunity for other sources to challenge the sole source determination by submitting a capability statement. Capability statements are due by April 9, 2026, 10:00 a.m. (Pacific).
Scope of Work
This BPA covers the procurement of Nitric Oxide (NO) gas for Neonatal Pediatric Inhaled Nitric Oxide (INO) therapy. Specific products include:
- NITRIC OXIDE 800 PPM GAS (1963 LITERS, NDC: 64693-0002-02)
- NITRIC OXIDE 800 PPM GAS (353 LITERS, NDC: 64693-0002-01)
Delivery locations will be determined by call orders, serving all Medical Treatment Facilities under the Defense Health Network Pacific Rim, including San Diego, CA.
Contract & Timeline
- Contract Type: Firm-fixed-price 5-Year Blanket Purchase Agreement (BPA)
- Period of Performance: Estimated June 1, 2026, to May 31, 2031
- Award Under: U.S. Department of Veteran Affairs contract number V797D-60737
- Published: March 25, 2026
- Capability Statement Due: April 9, 2026, 10:00 a.m. (Pacific)
Submission & Evaluation
This is not a request for competitive proposals; no solicitation document exists. Interested sources who believe they can meet the requirements must submit a capability statement (maximum 6 pages, 10-point font) demonstrating their ability to provide the required INO gas supply. Statements should include management, technical data, and cost information. Telephone requests or offers will not be honored. Capability statements will be reviewed solely to determine if a competitive procurement is feasible or if the sole source order will proceed.
Eligibility / Set-Aside
- NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing (Business size standard: 1,300 employees)
- PSC Code: 6505 - Drugs and Biologicals
- Set-Aside: None (Sole Source) The government has determined that INO THERAPEUTICS, LLC is the only source capable of meeting the minimum requirements, based on market research and previous acquisition history.